In our What’s New in ME/CFS? Series, we’respotlighting researchers who are not just studying this disease, but also helping to transform what’s possible.
This week, we sat down with Dr. Roshan Kumar, Head of Research at HiFiBiO Therapeutics and caregiver to a loved one with ME/CFS. His work focuses on T-cell dysfunction in ME/CFS and Long COVID. They are using advanced single-cell immune profiling to identify distinct biological patterns in patients.
“We’re seeing profound immune differences – even from small numbers of patients and controls. That means we’re identifying real biological subtypes. If we can define those subgroups, we can start designing treatments that actually work.”
—Dr. Roshan Kumar
This is the kind of shift the field has long needed: from asking if ME/CFS is biological, to uncovering how it works – and what can be done to treat it.
In this conversation, Roshan shares:
- Why dysfunctional T cells are a promising focus of research
- What it means to see meaningful immune signals in small cohorts
- How his personal experience as a caregiver shapes his work
- What gives him hope in the face of scientific and systemic barriers
- What he’d do with more funding—and how close we are to drug discovery
🎥 Watch the full interview here.
The field is reaching a turning point. Instead of scattered observations, we now have immune findings that point to clear subtypes. That’s what makes effective clinical trials possible.
Thank you for staying with us – and for helping keep this momentum going.